Back to top
more

Aphria Inc. (APHA)

(Delayed Data from NYSE)

$6.94 USD

6.94
5,631,062

-0.19 (-2.66%)

Updated May 3, 2019 04:02 PM ET

After-Market: $7.00 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Allscripts Unit Inks Deal to Boost Veradigm AccelRx Platform

by Zacks Equity Research

This deal is expected to bolster Allscripts' (MDRX) Clinical and Financial Solutions segment.

    Here's Why You Should Hold on to ResMed (RMD) Stock for Now

    by Zacks Equity Research

    Investors continue to be optimistic about ResMed (RMD) on its focus on digital health technology and robust demand for its critical care products.

      OPKO's BioReference Laboratories' Deal Brings Antibody Testing

      by Zacks Equity Research

      OPKO Health's (OPK) subsidiary, BioReference Laboratories collaborates with MagnaCare to offer antibody testing to Labor groups in New York metropolitan area.

      Myriad's (MYGN) EndoPredict Grows Amid Coronavirus Mayhem

      by Zacks Equity Research

      Within Molecular Diagnostics, Myriad Genetics (MYGN) registers strong sales for EndoPredict, myChoice CDx and BRACAnalysis CDx.

        Are Options Traders Betting on a Big Move in Aphria (APHA) Stock?

        by Zacks Equity Research

        Investors need to pay close attention to Aphria (APHA) stock based on the movements in the options market lately.

          Hologic's Second Molecular Test Gets EUA to Detect Coronavirus

          by Zacks Equity Research

          Hologic (HOLX) expects to boost testing capacity by combining its manufacturing ability for the latest EUA of test with its largest installed base of high-throughput molecular instruments.

            Here's Why You Should Retain Masimo Stock (MASI) For Now

            by Zacks Equity Research

            Investor confidence remains high in Masimo (MASI) stock, thanks to solid prospects.

              Here's Why You Should Retain Avanos Medical Stock for Now

              by Zacks Equity Research

              Avanos Medical (AVNS) continues to benefit from strong performing segments and robust product portfolio. However, stiff competition remains a concern.

              Nevro's (NVRO) Senza Omnia SCS System Gets CE Mark Approval

              by Zacks Equity Research

              Nevro (NVRO) received CE mark approval for the Senza Omnia SCS system, which is likely to boost its international presence.

              ResMed Grows on Solid Ventilator Sales Amid Coronavirus Woes

              by Zacks Equity Research

              ResMed (RMD) global sales increase on ramped-up demand for its critical care support products.

              STERIS' (STE) Q4 Earnings Surpass Estimates, Margins Rise

              by Zacks Equity Research

              STERIS' (STE) fourth-quarter fiscal 2020 results reflect strong segmental performance despite the coronavirus-led economic crisis.

              GNC Holdings' (GNC) Q1 Earnings and Sales Miss Estimates

              by Zacks Equity Research

              All the operating segments of GNC Holdings (GNC) register significant year-over-year sales decline in Q1 on coronavirus-led business disruption.

              AMN Healthcare (AMN) Q1 Earnings In Line With Estimates

              by Zacks Equity Research

              AMN Healthcare (AMN) gained from core operating segments in Q1.

              Intersect ENT (XENT) Reports Wider-Than-Expected Q1 Loss

              by Zacks Equity Research

              Intersect ENT (XENT) performs disappointingly in the first quarter of 2020 due to the coronavirus crisis.

              Here's Why You Should Retain Cardinal Health Stock for Now

              by Zacks Equity Research

              Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.

              Phibro (PAHC) Q3 Earnings Surpass Estimates, Margin Declines

              by Zacks Equity Research

              Phibro (PAHC) witnessed revenue uptick in its core Animal Health segment in Q3 despite the coronavirus-led business disruptions in the animal production industry.

              HMS Holdings (HMSY) Earnings and Revenues Beat Estimates in Q1

              by Zacks Equity Research

              HMS Holdings (HMSY) witnessed revenue growth at COB and PI segments in Q1.

              Allscripts (MDRX) Q1 Earnings and Revenues Miss Estimates

              by Zacks Equity Research

              Allscripts (MDRX) witnessed a decline in core Client Services and Software delivery unit revenues in Q1.

              National Vision (EYE) Q1 Earnings Top Estimates, Margin Falls

              by Zacks Equity Research

              National Vision's (EYE) first-quarter 2020 results were better than expected despite the coronavirus-led economic crisis.

              Integer Holdings (ITGR) Q1 Earnings & Revenues Top Estimates

              by Zacks Equity Research

              Integer Holdings' (ITGR) first-quarter results benefit from strength in Cardio & Vascular sub-segment and margin expansion.

              Zimmer Biomet (ZBH) Q1 Earnings Top, Revenues Miss Estimates

              by Zacks Equity Research

              The spread of coronavirus results in deferral of elective procedures for Zimmer Biomet (ZBH) in Q1.

              Insulet (PODD) Q1 Earnings Lag Estimates, Margins Decline

              by Zacks Equity Research

              Insulet's (PODD) first-quarter 2020 results reflect mixed segmental performance amid the coronavirus-led economic crisis.

              Fresenius Medical (FMS) Q1 Earnings Miss Estimates, Fall Y/Y

              by Zacks Equity Research

              Fresenius Medical's (FMS) first-quarter earnings benefit from strong segmental performance.

              Cardinal Health (CAH) Beats Q3 Earnings and Revenue Estimates

              by Zacks Equity Research

              Cardinal Health's (CAH) fiscal third-quarter results benefit from strong segmental performance.

              LHC Group (LHCG) Earnings and Revenues Beat Estimates in Q1

              by Zacks Equity Research

              LHC Group (LHCG) continues to gain from home health services and hospice admissions, which improved year over year in Q1.